In which coronary calcium score ranges should low‑dose aspirin (81 mg daily) be prescribed for primary prevention?

Low-Dose Aspirin for Primary Prevention Based on Coronary Artery Calcium Score

Consider low-dose aspirin (75-100 mg daily) for primary prevention when the coronary artery calcium (CAC) score is ≥100, provided the patient is 40-70 years old, has ≥5% 10-year ASCVD risk, and lacks high bleeding risk. 1

CAC Score Thresholds for Aspirin Therapy

CAC ≥100: Net Benefit Territory

• This is your primary threshold for considering aspirin. Multiple guidelines (SCCT, CSANZ, Chinese CPGs, NLA) converge on CAC ≥100 as the cutoff where aspirin benefits outweigh bleeding risks 1
• The number needed to treat (NNT) becomes favorable at this threshold: NNT5 of 140 versus number needed to harm (NNH5) of 518 2
• CAC ≥400 provides even stronger justification, with particularly robust net benefit regardless of other risk factors 1

CAC 1-99: Gray Zone

• Aspirin generally not recommended in this range
• Risk-benefit ratio remains unfavorable for most patients
• CSANZ explicitly recommends against aspirin for CAC <100 1

CAC = 0: Avoid Aspirin

• Do not prescribe aspirin when CAC = 0, as bleeding risk exceeds any potential benefit 1
• Exception: Only consider if ASCVD risk >20% (rare scenario) 1
• NNT5 of 1,190 versus NNH5 of 567 demonstrates clear net harm 2

Essential Patient Selection Criteria

Beyond the CAC score, you must verify:

Age Requirements

• 40-70 years old is the evidence-supported range 1, 3
• Age >70: potentially harmful due to elevated bleeding risk 3
• Age <40: insufficient evidence 3

ASCVD Risk Threshold

• Minimum ≥5% 10-year ASCVD risk required for benefit 1, 4
• Below 5% risk: aspirin causes net harm regardless of CAC score 1, 4

Bleeding Risk Assessment (Critical)

High bleeding risk is an absolute contraindication regardless of CAC score. Screen for:

• History of gastrointestinal bleeding or peptic ulcer disease
• Age >70 years
• Thrombocytopenia or coagulopathy
• Chronic kidney disease
• Concurrent NSAIDs, steroids, anticoagulants, or warfarin use 3, 5

If high bleeding risk exists, aspirin causes net harm even with CAC ≥100 4

Practical Algorithm

1. Confirm age 40-70 years
2. Calculate 10-year ASCVD risk (must be ≥5%)
3. Obtain CAC score
4. Screen for bleeding risk factors
5. Apply decision:
   • CAC ≥100 + low bleeding risk + ≥5% ASCVD risk → Consider aspirin 75-100 mg daily
   • CAC ≥400 → Stronger consideration for aspirin (especially robust benefit)
   • CAC 1-99 → Do not prescribe aspirin
   • CAC = 0 → Do not prescribe aspirin (unless ASCVD risk >20%, which is uncommon)
   • Any high bleeding risk → Do not prescribe aspirin

Strength of Evidence

The 2023 JACC Cardiovascular Imaging guideline review 1 synthesizes multiple international guidelines and represents the most comprehensive recent analysis. It shows remarkable consensus across American (SCCT), Australian (CSANZ), Chinese, and NLA guidelines on the CAC ≥100 threshold. The 2019 ACC/AHA Primary Prevention Guidelines 3 provide the foundational age and bleeding risk parameters but don't specify CAC cutoffs—this gap is filled by the specialized society recommendations that emerged subsequently.

Research from MESA 2 and Dallas Heart Study 4 provides the quantitative risk-benefit calculations supporting these thresholds, with consistent findings that CAC ≥100 shifts the balance toward net benefit while CAC = 0 indicates net harm.

Common Pitfalls

• Don't use aspirin for "moderate risk" without CAC scoring—traditional risk scores alone miss the mark for aspirin allocation 1, 2
• Don't ignore bleeding risk assessment—this trumps all other considerations 4
• Don't prescribe aspirin doses >100 mg—no additional ASCVD benefit but increased bleeding 3
• Don't continue aspirin in patients with CAC = 0 who were started empirically—the data supports discontinuation 2